CUPERTINO, Calif., June 3, 2011 /PRNewswire/ — DURECT
Corporation (Nasdaq:
DRRX) announced today that Jim Brown, President and CEO, will
be presenting at the Jefferies Healthcare Conference on Tuesday,
June 7 at 4:30 p.m. Eastern time.  The conference is being
held at the Grand Hyatt in New York.  

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by
accessing DURECT’s homepage at www.durect.com and clicking
“Investor Relations.”  If you are unable to participate during
the live webcast, the call will be archived on DURECT’s website
under Audio Archive in the “Investor Relations” section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing
innovative drugs for pain and other chronic diseases, with
late-stage development programs including REMOXY®,
POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.
 DURECT’s proprietary oral, transdermal and injectable
depot delivery technologies enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved
convenience, compliance, efficacy and safety for small molecule and
biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®,
and ELADUR™ are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners.
 REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities.

‘/>”/>

SOURCE